These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6390701)

  • 1. Treatment of Parkinson's disease with L-methionine.
    Smythies JR; Halsey JH
    South Med J; 1984 Dec; 77(12):1577. PubMed ID: 6390701
    [No Abstract]   [Full Text] [Related]  

  • 2. [L-Methionine treatment of Parkinson's disease: preliminary results].
    Meininger V; Flamier A; Phan T; Ferris O; Uzan A; Lefur G
    Rev Neurol (Paris); 1982; 138(4):297-303. PubMed ID: 7134722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic modification of Parkinson's disease and of chronic manganese poisoning.
    Cotzias GC; Papavasiliou PS; Ginos J; Steck A; Düby S
    Annu Rev Med; 1971; 22():305-26. PubMed ID: 4944422
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of L-dopa in Parkinson's disease.
    Godwin-Austen RB; Tomlinson EB; Frears CC; Kok HW
    Lancet; 1969 Jul; 2(7613):165-8. PubMed ID: 4183130
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comparative study on Parkopan, Amantadine and L-dopa in the treatment of Parkinson's disease].
    Dzudza M; Dzudza D
    Med Arh; 1974; 28(4):407-15. PubMed ID: 4613968
    [No Abstract]   [Full Text] [Related]  

  • 6. Parkinson's disease: trials and travesties.
    Morrish P
    Pract Neurol; 2007 Apr; 7(2):132. PubMed ID: 17430881
    [No Abstract]   [Full Text] [Related]  

  • 7. Quantitative measurements of L-dopa therapy in Parkinson's disease.
    Webster DD
    Neurology; 1970 Apr; 20(4):376-7. PubMed ID: 4935022
    [No Abstract]   [Full Text] [Related]  

  • 8. [Results of two new drugs in Parkinson's disease: L-dopa and amantadine].
    Sigwald J; Raymondeaud C; Piot C
    Rev Neurol (Paris); 1970 Feb; 122(2):145-8. PubMed ID: 4931718
    [No Abstract]   [Full Text] [Related]  

  • 9. Parkinson's disease: L-dopa treatment and handwriting area.
    Knopp W; Paulson G; Allen JN; Smeltzer D; Brown FD; Kose W
    Curr Ther Res Clin Exp; 1970 Mar; 12(3):115-25. PubMed ID: 4985489
    [No Abstract]   [Full Text] [Related]  

  • 10. The treatment with L-dopa and amantadine in Parkinson's disease.
    Pendefunda G; Pollingher B; Stefanache F; Gavril A; Oprisan C; Merling M; Nemteanu E; Ciunru M; Koropitzer I
    Ther Hung; 1975; 23(1):12-6. PubMed ID: 1105871
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of Parkinson's disease with L-dopa combined with a decarboxylase inhibitor].
    Siegfried J; Klaiber R; Perret E; Ziegler WH
    Dtsch Med Wochenschr; 1969 Dec; 94(52):2678-81. PubMed ID: 4903342
    [No Abstract]   [Full Text] [Related]  

  • 12. Early treatment of Parkinson's disease. Open studies are unreliable.
    Myllylä V; Heinonen E
    BMJ; 1994 Jan; 308(6923):272-3. PubMed ID: 8111278
    [No Abstract]   [Full Text] [Related]  

  • 13. [Evaluation of combined L-dopa-cyproheptadine therapy of patients with Parkinson's disease].
    Fodor M; Solymosi L; Szántó J
    Orv Hetil; 1980 Jul; 121(27):1631-6. PubMed ID: 7005809
    [No Abstract]   [Full Text] [Related]  

  • 14. The solvable problem of racial under-representation in Parkinson's disease clinical trials.
    Ridgway D
    Parkinsonism Relat Disord; 2009 May; 15(4):253. PubMed ID: 18790662
    [No Abstract]   [Full Text] [Related]  

  • 15. Amantadine treatment of Parkinson's disease.
    Boman K; Porras J
    Acta Neurol Scand; 1970; 46(S43):225-6. PubMed ID: 4917686
    [No Abstract]   [Full Text] [Related]  

  • 16. [Biochemical aspects of the effect of L-dopa in patients with Parkinson's disease].
    Gründig E; Gerstenbrand F; Oberhummer J; Simanyi M; Schedl R; Weiss J
    Z Neurol; 1972; 203(1):73-90. PubMed ID: 4118094
    [No Abstract]   [Full Text] [Related]  

  • 17. [L-Dopa therapy in Parkinson's disease. A double-blind study].
    Worm-Petersen J; Dupont E; Mikkelsen B
    Ugeskr Laeger; 1971 Nov; 133(47):2321-6. PubMed ID: 4944651
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
    Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Zamponi A
    Minerva Med; 1972 Dec; 63(89):4853-61. PubMed ID: 4566743
    [No Abstract]   [Full Text] [Related]  

  • 19. Age bias in clinical trials of Parkinson's disease treatment.
    Rajapakse A; Rajapakse S; Playfer J
    J Am Geriatr Soc; 2008 Dec; 56(12):2353-4. PubMed ID: 19093937
    [No Abstract]   [Full Text] [Related]  

  • 20. Continuing trials of GDNF in Parkinson's disease.
    Barker RA
    Lancet Neurol; 2006 Apr; 5(4):285-6. PubMed ID: 16545740
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.